$NTHI News

NeOnc Technologies Holdings Inc (NTHI) (Q2 2026) Earnings Call Highlights: First Annual Meeting ...

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

NeOnc Technologies shares jump after positive Phase 2a glioma results

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NeOnc Technologies Announces Topline Results From Its Phase 2A Portion Of NEO100-01 Study Of Intranasal NEO100 In Patients With Recurrent Or Progressive Glioma; Study Met Its Primary Endpoint; Will Request Type B Meeting With FDA

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NeOnc Technologies Q2 EPS $(0.58) Misses $(0.15) Estimate

NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors

NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

NeOnc Technologies Receives Written Feedback From FDA Regarding CMC Development Program For NEO212, Temozolomide-Perillyl Alcohol Conjugate; Co. Cancels July Meeting

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

NeOnc Technologies Granted Investigational New Drug Status From Abu Dhabi's Department Of Health For NEO100 To Treat Non-Invasive Nose-To-Brain Delivery

WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy

NeOnc Technologies Proceeding Ahead With Pipeline Of Therapies After Receiving Department of Health – Abu Dhabi Authorization For Its Investigational New Drug For NEO212 To Treat Aggressive Brain Tumors, Including Glioblastoma

NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

NeOnc Announces Abu Dhabi DOH Grants IND Status For NEO212, Orally Administered Perillyl Alcohol-Temozolomide Carbamate Conjugate Being Developed For Patients With Aggressive Brain Tumors

WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates

NeOnc Technologies Enters Securities Purchase Agreement For Up To $5,000,000 Of Its Convertible Preferred Stock At $833.34 Per Share, With Up To 6,000 Shares Authorized For Issuance